Genomic Health
Illuminating Breast Cancer Recurrence Risk
 |   > Search     |  
Home Genomic Health Contact Us Register Online Portal


About Oncotype DX

The Role of Oncotype DX

Oncotype DX Studies

Oncotype DX Logistics

Clinical Practice Guidelines

Health Insurance Coverage

The TAILORx Clinical Trial

Frequently Asked Questions


Updated NCCN Guidelines

Coming Soon ER and PR Scores

Healthcare Insurance


Welcome to Oncotype DX Logistics

Welcome to OncotypeDX.com for Healthcare Professionals

Oncotype DX® is a clinically validated, multi-gene assay that provides a quantitative assessment of the likelihood of distant breast cancer recurrence and also assesses the benefit from chemotherapy.ยน Oncotype DX is leading the way to individualized breast cancer treatment by providing valuable, patient-specific information used to assist authorized healthcare providers in optimizing treatment plans. Click here to learn more about Oncotype DX.
TAILORx




1 The data on chemotherapy benefit is derived from the NSABP Study B-20 which compared hormonal therapy alone versus CMF based chemotherapy and hormonal therapy.

What's New?

June 2, 2008
Genomic Health Announces Expansion of Oncotype DX(R) Breast Cancer Test to Include Quantitative Estrogen Receptor (ER) and Progesterone Receptor (PR) Scores

May 31, 2008
Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies



Ordering Resources
How to Order the Test
Order Forms
Online Reports
  © 2008 Genomic Health, Inc.  All rights reserved. | Home | Contact Us | Privacy | Terms and Conditions |